secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001140361-23-051195
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 4.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics dismisses auditor EisnerAmper, engages Grant Thornton; CEO and CFO exit
--------------------------------------------------------------------------------

- EisnerAmper dismissed as auditor; Grant Thornton Zhitong engaged as new independent registered public accounting firm.
- CEO Nassim Usman ceased as officer effective Oct 30, 2023; remains director; receives 12-month salary severance plus accelerated vesting.
- Interim CFO Seline Miller ceased as officer effective Oct 30, 2023; receives 9-month salary severance plus accelerated vesting.
- EisnerAmper’s prior reports included going-concern emphasis paragraphs related to convertible preferred stock cash settlement feature.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/0001140361-23-051195-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123051195/ny20009756x13_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-051195

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer